검색
Telix Pharmaceuticals Ltd
TLX관심 목록에 추가
11.950USD
+0.640+5.66%
종가 09-22 16:00（ET）
0.00시가총액
0.00P/E TTM
장전 거래 05:27 (ET)11.570USD-0.380-3.18%
장전 거래 05:27 (ET)Telix Pharmaceuticals Ltd 정보 회사
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Telix Pharmaceuticals Ltd 프로필
종목 코드 TLX
회사 이름Telix Pharmaceuticals Ltd
상장일Nov 15, 2017
CEOOrtiz (Raphaeel)
직원 수- -
유형Depository Receipt
회계 연도 종료- -
주소55 Flemington Road
도시MELBOURNE
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Australia
우편 번호3051
전화61390933855
웹사이트https://telixpharma.com/
종목 코드 TLX
상장일Nov 15, 2017
CEOOrtiz (Raphaeel)
Telix Pharmaceuticals Ltd의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Cade, M.D.
Dr. David Cade, M.D.
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Darren Smith, CPA
Mr. Darren Smith, CPA
Group Chief Financial Officer
Group Chief Financial Officer
--
--
Dr. Darren Patti, Pharm.D.
Dr. Darren Patti, Pharm.D.
Group Chief Operating Officer
Group Chief Operating Officer
--
--
Ms. Marie McDonald
Ms. Marie McDonald
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. David Gill
Mr. David Gill
Non-Executive Chair of the Board
Non-Executive Chair of the Board
--
--
Ms. Shomalin Naidoo
Ms. Shomalin Naidoo
Interim Company Secretary
Interim Company Secretary
--
--
Dr. Maria Rivas, M.D.
Dr. Maria Rivas, M.D.
Additional Non-Executive Director
Additional Non-Executive Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. David Cade, M.D.
Dr. David Cade, M.D.
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Darren Smith, CPA
Mr. Darren Smith, CPA
Group Chief Financial Officer
Group Chief Financial Officer
--
--
Dr. Darren Patti, Pharm.D.
Dr. Darren Patti, Pharm.D.
Group Chief Operating Officer
Group Chief Operating Officer
--
--
자주 묻는 질문
Telix Pharmaceuticals Ltd의 상위 5대 주주는 누구인가요?
Telix Pharmaceuticals Ltd의 상위 5대 주주는 다음과 같습니다: Dr. Christian P. (Chris) Behrenbruch, J.D., Ph.D.
Telix Pharmaceuticals Ltd(TLX)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Telix Pharmaceuticals Ltd의 주식을 보유한 기관은 총 61곳이며, 이들이 보유한 주식의 총 가치는 약 1.47M로 전체 발행 주식의 0.43%를 차지합니다. 이는 2025Q4 대비 326197.00 증가한 수치입니다.